THIRD HARMONIC BIO ($THRD) posted quarterly earnings results on Thursday, May 8th. The company reported earnings of -$0.35 per share, missing estimates of -$0.30 by $0.05. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $THRD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
THIRD HARMONIC BIO Insider Trading Activity
THIRD HARMONIC BIO insiders have traded $THRD stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $THRD stock by insiders over the last 6 months:
- EDWARD R. CONNER (Chief Medical Officer) sold 2,117 shares for an estimated $31,755
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
THIRD HARMONIC BIO Hedge Fund Activity
We have seen 63 institutional investors add shares of THIRD HARMONIC BIO stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BML CAPITAL MANAGEMENT, LLC added 3,824,417 shares (+inf%) to their portfolio in Q1 2025, for an estimated $13,270,726
- FMR LLC added 2,228,549 shares (+723.6%) to their portfolio in Q4 2024, for an estimated $22,931,769
- BVF INC/IL removed 1,993,000 shares (-45.6%) from their portfolio in Q4 2024, for an estimated $20,507,970
- COMMODORE CAPITAL LP removed 1,122,865 shares (-82.5%) from their portfolio in Q4 2024, for an estimated $11,554,280
- DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) added 1,019,700 shares (+inf%) to their portfolio in Q4 2024, for an estimated $10,492,713
- MILLENNIUM MANAGEMENT LLC added 558,616 shares (+685.7%) to their portfolio in Q4 2024, for an estimated $5,748,158
- ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC removed 505,573 shares (-4.6%) from their portfolio in Q4 2024, for an estimated $5,202,346
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
